Zoom offers a rare value opportunity in large-cap software, trading at ultra-low P/E multiples amid renewed growth acceleration and robust buyback activity. ZM's aggressive share repurchases, ...

Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with ...